Skin Neoplasms News - LARVOL Sigma

Skin Neoplasms	Welcome, Profile Billing Logout

«1 2 3 4 567 »

||||||||||  Zelboraf (vemurafenib) / Roche
Enrollment change, Metastases:  Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (clinicaltrials.gov) -  Mar 13, 2013
P2, N=2, Terminated,  Sponsor: Memorial Sloan-Kettering Cancer Center
N=22 --> 2

||||||||||  carboplatin / Generic mfg., temozolomide / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Metastases:  Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma (clinicaltrials.gov) -  Mar 13, 2013
P2, N=50, Active, not recruiting,  Sponsor: New Mexico Cancer Care Alliance
N=22 --> 2 Recruiting --> Active, not recruiting

||||||||||  celecoxib oral / Generic mfg.
Enrollment change:  Celecoxib in Preventing Skin Cancer (clinicaltrials.gov) -  Mar 6, 2013
P2, N=0, Withdrawn,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=36 --> 0

|||||||||| New P2/3 trial: A Randomized Control Trial of Sun Protection Interventions for Operating Engineers (clinicaltrials.gov) - Mar 3, 2013
P2/3, N=256, Active, not recruiting, Sponsor: University of Michigan

||||||||||  imatinib / Generic mfg.
Enrollment change, Metastases:  S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov) -  Feb 26, 2013
P2, N=40, Completed,  Sponsor: National Cancer Institute (NCI)
N=36 --> 0 N=23 --> 40

||||||||||  sirolimus / Generic mfg.
New P4 trial:  PROSKIN: Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol (clinicaltrials.gov) -  Feb 20, 2013
P4, N=40, Terminated,  Sponsor: University Hospital of Berlin

|||||||||| Trial initiation date: A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies (clinicaltrials.gov) - Feb 18, 2013
P=N/A, N=40, Not yet recruiting, Sponsor: Stanford University
N=23 --> 40 Initiation date: Dec 2009 --> Dec 2013

|||||||||| Enrollment change: NPEF: Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer (clinicaltrials.gov) - Feb 18, 2013
P1, N=4, Completed, Sponsor: Children's Hospital & Research Center Oakland
Initiation date: Dec 2009 --> Dec 2013 N=26 --> 4

|||||||||| Trial completion: NPEF: Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer (clinicaltrials.gov) - Feb 18, 2013
P1, N=4, Completed, Sponsor: Children's Hospital & Research Center Oakland
N=26 --> 4 Recruiting --> Completed

|||||||||| Trial completion: Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule (clinicaltrials.gov) - Feb 6, 2013
P1, N=5, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment open: Post-Approval Study of MelaFind (clinicaltrials.gov) - Jan 9, 2013
P=N/A, N=720, Recruiting, Sponsor: MELA Sciences, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  sirolimus / Generic mfg.
New P2 trial:  Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma (clinicaltrials.gov) -  Jan 7, 2013
P2, N=43, Recruiting,  Sponsor: University of Florida

|||||||||| Trial termination, Metastases: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes (clinicaltrials.gov) - Jan 3, 2013
P2, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Completed --> Terminated; Low accrual

|||||||||| Trial initiation date: Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation (clinicaltrials.gov) - Dec 20, 2012
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Low accrual Initiation date: Oct 2011 --> Aug 2012

||||||||||  epacadostat (INCB024360) / Incyte
Enrollment open, Combination therapy, Metastases:  A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) -  Dec 12, 2012
P1/2, N=136, Recruiting,  Sponsor: Incyte Corporation
Initiation date: Oct 2011 --> Aug 2012 Active, not recruiting --> Recruiting

|||||||||| Trial termination, Metastases: Drosophila-generated CTL (clinicaltrials.gov) - Dec 11, 2012
P2, N=3, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Completed --> Terminated; Study was terminated due to withdrawal of CRADA partner.

||||||||||  Hiltonol (poly-ICLC) / Oncovir
Enrollment closed, IO biomarker:  Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (clinicaltrials.gov) -  Dec 11, 2012
P2, N=33, Active, not recruiting,  Sponsor: Dr. Nina Bhardwaj
Completed --> Terminated; Study was terminated due to withdrawal of CRADA partner. Recruiting --> Active, not recruiting

|||||||||| Trial completion, Metastases: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes (clinicaltrials.gov) - Nov 13, 2012
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment change: Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma (clinicaltrials.gov) - Nov 11, 2012
P=N/A, N=100, Terminated, Sponsor: New Mexico Cancer Care Alliance
Active, not recruiting --> Completed N=150 --> 100

||||||||||  Young TIL / National Cancer Institute
Trial completion, Metastases:  Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma (clinicaltrials.gov) -  Nov 7, 2012
P2, N=158, Completed,  Sponsor: National Cancer Institute (NCI)
N=150 --> 100 Active, not recruiting --> Completed

|||||||||| Trial completion, Surgery: Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients (clinicaltrials.gov) - Nov 4, 2012
P2, N=8, Completed, Sponsor: Healthpoint
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion, Preclinical: The Effect of Green Tea and Vitamin C on Skin Health (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=95, Completed, Sponsor: University of Manchester
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  gefitinib / Generic mfg.
Trial completion, Metastases:  ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (clinicaltrials.gov) -  Oct 22, 2012
P2, N=40, Completed,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Samcyprone (diphenylcyclopropenone) / Phio Pharma
New P1 trial, IO biomarker, Immunomodulating:  Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) -  Oct 18, 2012
P1, N=13, Recruiting,  Sponsor: Rockefeller University

||||||||||  tazarotene topical / Generic mfg.
Trial completion:  Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back (clinicaltrials.gov) -  Oct 2, 2012
P2, N=42, Completed,  Sponsor: Children's Hospital & Research Center Oakland
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=289, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment change:  Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (clinicaltrials.gov) -  Sep 19, 2012
P1, N=21, Active, not recruiting,  Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=50 --> 21

||||||||||  Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed:  Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (clinicaltrials.gov) -  Sep 19, 2012
P1, N=21, Active, not recruiting,  Sponsor: Roswell Park Cancer Institute
N=50 --> 21 Recruiting --> Active, not recruiting

||||||||||  erlotinib / Generic mfg.
Enrollment closed, Surgery:  Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin (clinicaltrials.gov) -  Sep 11, 2012
P2, N=40, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Enrollment change:  Can We Miss Pigmented Lesions in Psoriasis Patients? (clinicaltrials.gov) -  Aug 20, 2012
P4, N=6, Completed,  Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting N=10 --> 6

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Trial completion:  Can We Miss Pigmented Lesions in Psoriasis Patients? (clinicaltrials.gov) -  Aug 20, 2012
P4, N=6, Completed,  Sponsor: University of Alabama at Birmingham
N=10 --> 6 Recruiting --> Completed

|||||||||| Trial initiation date: New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=277, Recruiting, Sponsor: Norwegian University of Science and Technology
Recruiting --> Completed Initiation date: Jan 2012 --> Jun 2012

|||||||||| Enrollment open: New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=277, Recruiting, Sponsor: Norwegian University of Science and Technology
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting

|||||||||| Clinical: Sun Protection of Kidney Transplant Recipients (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=367, Not yet recruiting, Sponsor: Northwestern University

||||||||||  itraconazole / Generic mfg.
Biomarker, Trial suspension:  Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas (clinicaltrials.gov) -  Jul 10, 2012
P2, N=15, Suspended,  Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Suspended

||||||||||  itraconazole / Generic mfg.
Biomarker, Enrollment change:  Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas (clinicaltrials.gov) -  Jul 10, 2012
P2, N=15, Suspended,  Sponsor: Stanford University
Recruiting --> Suspended N=30 --> 15

|||||||||| Enrollment change: Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer (clinicaltrials.gov) - Jun 23, 2012
P=N/A, N=81, Completed, Sponsor: Massachusetts General Hospital
N=30 --> 15 N=120 --> 81

|||||||||| Enrollment change: Sun Protection for Florida's Children (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=2984, Completed, Sponsor: University of South Florida
N=120 --> 81 N=2000 --> 2984

|||||||||| Trial completion: Sun Protection for Florida's Children (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=2984, Completed, Sponsor: University of South Florida
N=2000 --> 2984 Recruiting --> Completed

|||||||||| Trial completion, Adherence: Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use (clinicaltrials.gov) - Jun 15, 2012
P0, N=70, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  epacadostat (INCB024360) / Incyte
New P1/2 trial, Combination therapy, Metastases:  A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) -  May 22, 2012
P1/2, N=136, Recruiting,  Sponsor: Incyte Corporation

|||||||||| Enrollment change, Metastases: Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma (clinicaltrials.gov) - Apr 13, 2012
P2, N=10, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=65 --> 10

|||||||||| Trial completion, Metastases: Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma (clinicaltrials.gov) - Apr 13, 2012
P2, N=10, Completed, Sponsor: National Cancer Institute (NCI)
N=65 --> 10 Recruiting --> Completed

|||||||||| Enrollment change: Comparison of Standard of Care or Treatment on Protocol (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Completed N=2000 --> 13

||||||||||  sirolimus / Generic mfg.
Review, Enrollment change, Journal:  Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients (clinicaltrials.gov) -  Apr 8, 2012
P4, N=86, Completed,  Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
N=2000 --> 13 N=200 --> 86

||||||||||  Young TIL / National Cancer Institute
Enrollment change, Metastases:  Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... (clinicaltrials.gov) -  Apr 5, 2012
P2, N=12, Completed,  Sponsor: National Cancer Institute (NCI)
N=200 --> 86 N=147 --> 12

||||||||||  Young TIL / National Cancer Institute
Trial completion, Metastases:  Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... (clinicaltrials.gov) -  Apr 5, 2012
P2, N=12, Completed,  Sponsor: National Cancer Institute (NCI)
N=147 --> 12 Recruiting --> Completed

||||||||||  ALVAC gp100 / Sanofi
Trial termination, Metastases:  Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma (clinicaltrials.gov) -  Mar 13, 2012
P2, N=3, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated; The study was terminated due to low accrual.

|||||||||| Trial termination, Metastases: Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma (clinicaltrials.gov) - Mar 12, 2012
P2, N=4, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; The study was terminated due to low accrual. Completed --> Terminated; The study was terminated due to low accrual.

|||||||||| Trial completion: Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer (clinicaltrials.gov) - Feb 27, 2012
P=N/A, N=81, Completed, Sponsor: Massachusetts General Hospital
Completed --> Terminated; The study was terminated due to low accrual. Recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites